[ad_1] The main problem Regeneron (REGN) has enjoyed tremendous success in the stock market for almost 7 years since the approval of its mega-blockbuster drug for retinal diseases, Eylea, by the FDA. …
Read More »How Libtayo's Approval Could Help Heal Regeneron's Persistent Diseases – Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
